Study procedures | Intervention period (Day of Release/Randomization-Month 6) | Post-Intervention | |||
---|---|---|---|---|---|
Baseline | Month 1 | Month 3 | Month 6 | Month 12 | |
Activity and biological tests | Â | Â | Â | Â | Â |
 Project screening | X |  |  |  |  |
 Consent & randomization | X |  |  |  |  |
 HIV rapid test or viral load based on status | X |  |  | X | X |
 Hepatitis C rapid test or viral load based on status | X |  |  | X | X |
 Sustained preexposure prophylaxis/antiretroviral therapy adherence (dried tenofovir blood spot) |  |  |  | X |  |
 Urine tenofovir |  |  | X | X | X |
 Urine substance use toxicology | X |  | X | X | X |
 Testing for sexually transmitted infections (gonorrhea, chlamydia, hepatitis B, and syphilis) | X |  |  | X |  |
Interview assessments | Â | Â | Â | Â | Â |
 Demographics | X |  |  |  |  |
 HIV risk behaviors | X |  | X | X | X |
 Timeline followback (self-reported daily opioid and stimulant use) | X |  | X | X | X |
 Patient Reported Outcome Measurement Information System (PROMIS) for Quality of Life | X |  | X | X | X |
 Patient Health Questionnaire (PHQ9; depression) | X |  | X | X | X |
 Visual Analog Scales (VAS) for antiretroviral therapy/preexposure prophylaxis/medication for opioid use disorder adherence |  | X | X | X | X |
 Texas Christian University (TCU) Drug Screen | X |  | X | X | X |
 Engagement in care (prescription refill for preexposure prophylaxis, antiretroviral therapy, medication for opioid use disorder) |  | X | X | X | X |
 Overdose and adverse events |  |  X | X | X | X |
 Craving for opioids and stimulants | X |  | X | X | X |
Incentives* | $50 | $50 | $50 | $75 | $75 |